Synonym
ABT-281; ABT281; ABT 281; A-86281; A86281; A 86281; Ascrolimus
IUPAC/Chemical Name
unknown
InChi Key
HIEKJRVYXXINKH-ADVKXBNGSA-N
InChi Code
InChI=1S/C44H69N5O11/c1-10-31-18-25(2)17-26(3)19-37(57-8)40-38(58-9)21-28(5)44(55,60-40)41(52)42(53)48-16-12-11-13-33(48)43(54)59-39(29(6)34(50)23-35(31)51)27(4)20-30-14-15-32(36(22-30)56-7)49-24-45-46-47-49/h18,20,24,26,28-34,36-40,50,55H,10-17,19,21-23H2,1-9H3/b25-18+,27-20+/t26-,28+,29+,30-,31+,32-,33-,34-,36+,37-,38-,39+,40+,44+/m0/s1
SMILES Code
CC[C@@H]1/C=C(C[C@@H](C[C@@H]([C@H]2O[C@]([C@@H](C[C@@H]2OC)C)(C(C(N3CCCC[C@H]3C(O[C@H](/C(C)=C/[C@@H]4CC[C@H](N5C=NN=N5)[C@H](OC)C4)[C@@H]([C@H](CC1=O)O)C)=O)=O)=O)O)OC)C)\C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
844.06
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Mollison KW, Fey TA, Gauvin DM, Sheets MP, Smith ML, Pong M, Krause R, Miller L, Or YS, Kawai M, Wagner R, Wiedeman PE, Clark RF, Gunawardana IW, Rhoades TA, Henry CL, Tu NP, BaMaung NY, Kopecka H, Liu L, Xie Q, Lane BC, Trevillyan JM, Marsh K, Luly JR, et al. Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. Curr Pharm
Des. 1998 Oct;4(5):367-79. Review. PubMed PMID: 10197049.
2: Mollison KW, Fey TA, Gauvin DM, Kolano RM, Sheets MP, Smith ML, Pong M, Nikolaidis NM, Lane BC, Trevillyan JM, Cannon J, Marsh K, Carter GW, Or YS, Chen YW, Hsieh GC, Luly JR. A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases. J Invest Dermatol. 1999 May;112(5):729-38. PubMed PMID: 10233764.